Abstract
Optimized deep brain stimulation (DBS) is fast becoming a therapy of choice for the treatment of Parkinson’s disease (PD). However, the post-operative optimization (patient clinical benefits are maximized and adverse effects are minimized) of the large number of possible DBS parameter settings (signal frequency, voltage, pulse width and contact locations) using the current empirical protocol requires numerous clinical visits, which substantially increases the time to reach optimal DBS stimulation, patient cost burden and ultimately limits the number of patients who can undergo DBS treatment. These issues became even more problematic with the recent introduction of electrode models with stimulation directionality thereby enabling more complex stimulation paradigms. These difficulties have necessitated the search for a biomarker-based optimization method that will streamline the DBS optimization process. Our recently published functional magnetic resonance imaging (fMRI) and machine learning-assisted DBS parameter optimization for PD treatment has provided a way to rapidly classify DBS parameters using parcel-based features that were extracted from DBS-fMRI response maps. However, the parcel-based method had limited accuracy as the parcels are based on subjective literature review. Here, we propose an unsupervised autoencoder (AE) based extraction of features from the DBS-fMRI responses to improve this accuracy. We demonstrate the usage of the extracted features in classification methods such as multilayer perceptron (MLP), random forest (RF), support vector machine (SVM), k-nearest neighbors (KNN) and LDA. We trained and tested these five classification algorithms using 122 fMRI response maps of 39 PD patients with a priori clinically optimized DBS parameters. Further, we investigated the robustness of the AE-based feature extraction method to changes in the activation patterns of the DBS-fMRI responses, which may be caused by difference in stimulation side and disease condition. Changes in the locations of activated and deactivated brain regions was simulated using a left-right horizontal flipping of the original left-sided (or nominal) DBS-fMRI response maps. The visualization of AE-based features extracted from the nominal and flipped DBS-fMRI response maps formed optimal and non-optimal clusters in a neuro-functionally meaningful manner, which indicate robustness of the AE-based feature extraction to subtle differences in the activated regions of DBS-fMRI response maps. The MLP, RF, SVM and LDA methods gave an overall DBS parameter classification accuracy of 96%, 94%, 92% and 93% respectively when trained using the AE-extracted features from the nominal DBS-fMRI maps. The AE-based MLP, RF, SVM and LDA accuracies were higher than the overall accuracy (81%) of our initial parcel-based LDA method. The performance of an AE-MLP model trained using the nominal DBS-fMRI maps did not change significantly when the model was tested on the flipped DBS-fMRI responses. We showed that the MLP method combined with AE-based feature extraction is best suited for fMRI-based DBS parameter optimization and represents another step towards a proposed digital tool for rapid semi-automated biomarker-based DBS optimization.
Competing Interest Statement
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Afis Ajala, Jianwei Qiu, John Karigiannis, Radhika Madhavan, Desmond Yeo, Luca Marinelli and Thomas Foo are salaried employees of GE Global Research. Andres Lozano is a consultant and advisor to Functional Neuromodulation, Medtronic, Boston Scientific, Abbott and Insightech.
Clinical Trial
NCT03153670
Funding Statement
This work was supported by the Michael J. Fox foundation [grant number MJFF-008877, 2019]; the Canadian Institutes of Health Research Banting fellowship [grant number 471913, 2022].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data used in this work were acquired after protocols were approved by the institutional research ethics board at the University Health Network, Toronto, Canada.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets analyzed in this research are not publicly available due to data privacy regulations of patient data. Upon reasonable request, the study protocol and individual de-identified participants' raw fMRI data will be available to investigators from the corresponding author using private online cloud storage. Researchers wishing to validate or replicate this work using the same datasets would need to be approved by the research boards of University of Toronto, University Health Network and GE Global Research.
